Clinical Trials

Phase II trial of capmatinib demonstrates positive results in NSCLC

Novartis said that the phase II GEOMETRY mono-1 trial of investigational medicine capmatinib (INC280) has demonstrated positive results in patients with MET mutated advanced non-small cell lung cancer (NSCLC).

Lynparza reduces disease progression risk in ovarian cancer study

A phase III trial has demonstrated that Lynparza maintenance therapy reduced risk of disease progression or death by 70% in patients with newly-diagnosed, advanced BRCA-mutated ovarian cancer.

Daiichi Sankyo launches phase 1 trial of DS-1205 in EGFR-mutated NSCLC

Daiichi Sankyo has dosed the first patient in a phase 1 trial evaluating its AXL inhibitor DS-1205 in combination with gefitinib in patients with metastatic or unresectable epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have progressed on therapy with tyrosine kinase inhibitors (TKIs).

Roche’s Kadcyla reduces disease recurrence risk in breast cancer study

Roche’s Kadcyla (trastuzumab emtansine) has significantly reduced the risk of disease recurrence or death compared to Herceptin (trastuzumab) in people with HER2-positive early breast cancer (eBC) in the phase III Katherine study.

Mereo completes patient enrollment for brittle bone disease trial

Mereo BioPharma Group, a UK-based specialty biopharma company, has completed patient enrollment for a phase 2b clinical trial of BPS-804 (Setrusumab) for the treatment of osteogenesis imperfecta (OI).

MaaT Pharma doses first patient in phase 2 trial of biotherapeutic to treat acute GvHD

MaaT Pharma has dosed first patient in a phase 2 clinical trial of its lead microbiome restoration candidate, MaaT013, in patients with steroid-resistant acute Graft-versus-Host-Disease (SR-aGvHD).

MEI, BeiGene to assess ME-401-Zanubrutinib combo in B-cell malignancies

MEI Pharma and BeiGene have entered into a clinical collaboration to evaluate the safety and efficacy of the combination of their respective drugs ME-401, an investigational PI3K delta inhibitor, and zanubrutinib, an investigational BTK inhibitor, for the treatment of patients with B-cell malignancies.

BMS, Compugen to evaluate Opdivo-COM701 combo in advanced solid tumors

Bristol-Myers Squibb (BMS) and Compugen have agreed to evaluate the safety and tolerability of the combination of Opdivo (nivolumab) and COM701, their respective drugs, for the treatment of patients with advanced solid tumors.

MaxCyte begins dosing in phase I solid tumors clinical trial

MaxCyte has dosed the first patient in its US phase I dose-escalation clinical trial of chimeric antigen receptor (CAR) therapeutic candidate, MCY-M11.